Twenty selected publications from CIC’s 2024-2025 scientific activity — ten where CIC is the corresponding institution and ten in which CIC researchers were main co-authors — spanning multiple myeloma, breast, lung, pancreatic and liver cancer, genome stability and precision oncology.
Twenty selected publications from the 2024–2025 period, grouped by CIC’s role. Each links to its source article via DOI.
Ten selected publications where CIC is the corresponding institution.
This trial asked whether treating pre-symptomatic high-risk myeloma early and aggressively could prevent the disease from developing. One in three patients showed no detectable disease four years later — suggesting a curative strategy may be possible.
Every time a cell divides, it must copy its DNA accurately. CIC researchers identified a previously unknown role for an enzyme called Ubp10 in ensuring this process is completed correctly — adding a new piece to our understanding of how cells protect their genetic code.
For a healthy pregnancy, eggs and sperm must form with the right number of chromosomes. CIC researchers found that a protein called RNF212B is essential for this process — and that without it, chromosomes separate incorrectly, causing infertility and conditions like Down syndrome.
RASopathies are rare developmental disorders caused by overactivation of a key cellular pathway. CIC researchers discovered a new way this can happen — when two proteins are lost simultaneously, a third overcompensates — shedding new light on how these disorders arise.
CIC researchers discovered that blocking two enzymes — NOX1 and NOX4 — can slow tumor growth in this rare and aggressive liver cancer, offering a new and more targeted treatment avenue for a disease that urgently needs better options.
After intensive chemotherapy, the body struggles to rebuild blood cell production. CIC researchers found that a protein called C3G helps speed up this recovery, pointing to new strategies to help patients bounce back faster after treatment.
CIC researchers developed a new test far more sensitive than existing ones for detecting a key marker of mast cell disease. With it, one in five patients previously told they did not have a clonal disease turned out to have one — changing how they should be treated.
Hormonal therapies work well for many breast cancer patients — until they stop working. CIC researchers uncovered a molecular switch that allows tumor cells to bypass hormonal control, opening new ways to predict and overcome treatment resistance in HER2-positive breast cancer.
Pancreatic cancer is one of the hardest cancers to treat. CIC researchers designed a new type of drug that delivers a toxic payload directly to pancreatic tumor cells — and showed it can stop tumor growth and induce regression in experimental models.
CIC researchers discovered that a protein called Capicua normally acts as a brake on lung tumor development — and that the KRAS mutation that drives many lung cancers works partly by disabling this brake. Restoring it slowed tumor growth and improved sensitivity to existing drugs.
